Latest Headlines
-
DNA Labs International Acquires Intermountain Forensics Laboratory Operations, Boosts Capabilities With WGS Technology
7/15/2024
DNA Labs International (DLI), a leading privately owned accredited forensic DNA laboratory, is thrilled to announce the finalized acquisition of the laboratory operations of Intermountain Forensics (IMF), a non-profit DNA laboratory renowned for its commitment to high-quality forensic services.
-
Children's Hospital Of Richmond At VCU Opens Region's First Pediatric Cardiac Catheterization And Electrophysiology Lab
7/12/2024
A cardiac catheterization and electrophysiology lab is now open in the Children’s Tower. The new lab is the first dedicated cardiac procedure suite of its kind in the region, allowing for minimally invasive testing and procedures in a pediatric-specific environment.
-
MGI Tech And Predica Diagnostics Team Up For Precision RNA Sequencing In Oncology
7/11/2024
MGI (MGI Tech Co., Ltd. or its subsidiaries, together referred to MGI), a company committed to building core tools and technologies that drive innovation in life science, today announced the collaboration with Predica Diagnostics, a leading innovator in oncology diagnostics, to develop Predica's targeted RNA sequencing tests on the cost-effective MGI Next-generation sequencing platforms.
-
Thermo Fisher Scientific To Help Advance Myeloid Cancer Clinical Research And Treatment Utilizing Next Generation Sequencing Technology
7/11/2024
To help accelerate research into new treatments for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), Thermo Fisher Scientific Inc., the world leader in serving science, is partnering with the National Cancer Institute (NCI) – part of the National Institutes of Health – on the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial.
-
DCN Dx's Clinical Research Helps Secure FDA Authorization For Cepheid HCV Test
7/10/2024
DCN Dx, a global leader in IVD CDMO and CRO services, is proud to amplify the news that the U.S. Food and Drug Administration (FDA) has granted De Novo marketing authorization with Clinical Laboratory Improvement Amendments (CLIA) Waiver for the Cepheid Xpert HCV test.
-
Babson Diagnostics Launches BetterWay Across Austin
7/10/2024
Babson Diagnostics, a science-first healthcare technology company, is excited and proud to announce the launch of its groundbreaking blood testing service.
-
Quest Diagnostics To Acquire Outreach Laboratory Services Of Ohiohealth
7/10/2024
Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, and OhioHealth, a nationally recognized not-for-profit, charitable, integrated health system, today announced a definitive agreement for Quest to acquire select assets of OhioHealth's outreach laboratory services business.
-
Introducing Our New MassBioedge Preferred Partner In Lab Operations: Service Insight
7/9/2024
MassBio is proud to announce Service Insight, a leading innovator in AIoT powered asset management and monitoring solutions, as the Preferred Lab Operations Platform Partner for the MassBioEdge program.
-
HNL Lab Medicine Launches Digital Pathology Program
7/9/2024
HNL Lab Medicine is excited to announce the integration of advanced digital pathology services into its diagnostic offerings, marking a significant milestone in the evolution of patient care and diagnostic precision.
-
Mymycolab, LLC Teams Up With Evexia Diagnostics To Distribute Personalized Mycotoxin Testing To 20,000 Clinicians
7/9/2024
MymycoLab, LLC, the leading laboratory for testing for mycotoxins from toxic molds, today announced a new distribution agreement with Evexia Diagnostics to bring MymycoLab’s personalized Mycotoxin testing technology to Evexia’s 20,000 clinical practitioners.